Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00142896 · ClinicalTrials.gov registry record · Phase 2
Tramadol to Reduce Opioid Withdrawal Symptoms
A Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00142896 is a Phase 2 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 16 participants.
The verdict
NCT00142896, a Phase 2 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
Individuals with opioid addiction often experience serious withdrawal symptoms that may make relapse unavoidable. Tramadol, a medication that is currently used to treat pain caused by chronic conditions such as cancer or joint pain, may also be effective at reducing opioid withdrawal symptoms. This study will evaluate the effectiveness of tramadol at reducing withdrawal symptoms in individuals addicted to opioid drugs.
Interventions
- DRUG Naloxone
- DRUG Morphine
- DRUG Tramadol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2005-02 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00142896
The ClinicalTrials.gov registry entry for NCT00142896 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Naloxone is the first listed.
NCT00142896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00142896 about?
NCT00142896 is a clinical study titled "Tramadol to Reduce Opioid Withdrawal Symptoms". Individuals with opioid addiction often experience serious withdrawal symptoms that may make relapse unavoidable. Tramadol, a medication that is currently used to treat pain caused by chronic conditions such as cancer or joint pain, may also be effective at reducing opioid withdrawal symptoms. This ...
What is the current status of trial NCT00142896?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2005-02. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00142896?
The interventions under investigation include: Naloxone (DRUG), Morphine (DRUG), Tramadol (DRUG).
Who is sponsoring clinical trial NCT00142896?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.